A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients

This study has been terminated.
Astellas Pharma US, Inc.
Information provided by:
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
First received: January 24, 2006
Last updated: June 6, 2012
Last verified: June 2012

January 24, 2006
June 6, 2012
November 2003
Not Provided
Incidence of biopsy confirmed acute rejection (Banff Grade ≥ I) at 6 months.
Not Provided
Complete list of historical versions of study NCT00282230 on ClinicalTrials.gov Archive Site
  • 6 month patient and graft survival rates
  • time to first biopsy confirmed acute rejection
  • clinically treated acute rejection episodes
  • treatment failure (up to 6 months)
  • renal function (SrCl and CrCl)
  • quantitation of CMV and polyomavirus viral load
Not Provided
Not Provided
Not Provided
A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Prograf®/FK778 and Prograf®/MMF in De Novo Kidney Transplant Recipients

A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients

Not Provided
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Kidney Transplantation
Drug: FK778
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
October 2005
Not Provided

Inclusion Criteria:

  • Patient is a recipient of a primary or retransplanted cadaveric or non-HLA-identical living donor kidney.
  • Patient must receive first oral dose of randomized study drug within 48 hours of transplant procedure.

Exclusion Criteria:

  • Patient has received or is receiving an organ transplant other than kidney
  • Patient has received a kidney transplant from a cadaveric donor >= 60 years of age.
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Astellas Pharma Inc
Astellas Pharma US, Inc.
Study Director: John Holman, MD Astellas Pharma US, Inc.
Astellas Pharma Inc
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP